-
Security Type
-
Common Stock
-
Min Investment
-
$100
-
Offering Date
-
August 24, 2021
-
Expected Close Date
-
April 29, 2022
-
Target Raise
-
$10.00K-$3.93M
-
Security Price
-
$2.09
Company Description
The team at Lifebridge 10000 continues building its patent-pending LB10000 device, built from the ground up for late-stage cancer patients with metastatic disease in two or more locations on the body at once. Future patients treating metastatic cancer with Tumor Treating Fields (TTF) will not be left with the painful decision of what cancer to treat and which to let grow.
Key Deal Facts
Our device can extend the proven benefits of Tumor Treating Fields (TTF) therapy to patients with metastatic cancer.
On any given day 500,000+ cancer patients could be helped by our therapy. Without it they will die.
Value creation! Tumor Treating Fields has experienced explosive growth up 736% since 2018 (Forbes).
We solve the limitations of the current therapy. 2 U.S. Patents 3rd pending. Pending in 36 counties.
Use of Proceeds
- Operational & Personnel Expenses
- New Patents, Legal, Software
- Completion of IDE, ATTIF Systems for Animal Study and Human Pilot
- Patient Pilot Trial Expenses
Management Team / Advisory Board Bios
Peter F Travers, CEO and Founder, Managing Member of LifeBridge
He has a BA in communication from UCF. His first company was a medical ed firm that sold materials he created. He designed a marketing program that sold the training products to 3,000 hospitals.
Lee Zehngebot M.D., Medical Advisor
Dr. Lee Zehngebot has served as the Director of Clinical Research, Florida Hospital Cancer Institute in Orlando since 2007 and has participated as Principal Investigator and Co-Investigator on numerous clinical studies. Medical advisor to the company.
Ken Watkins, Founding Member and Chief Technologist
Mr. Watkins has 40 years of experience in the electronic engineering field, including 17 with Northrop Grumman Corp. While at Northrup he was responsible for 30 electrical engineers.
